{"disease":{"id":"breast-cancer-metastatic-breast-cancer","name":"breast cancer metastatic breast cancer"},"drugs":{"marketed":[{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05217381","title":"Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status","phase":"","overall_status":"COMPLETED","enrollment_count":18533,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT03577197","title":"Southeast Netherlands Advanced Metastatic Breast Cancer Registry","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Academisch Ziekenhuis Maastricht","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03280303","title":"Palbociclib in Real World Practice","phase":"","overall_status":"COMPLETED","enrollment_count":1285,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05945732","title":"DESTINY Breast Respond HER2-low Europe","phase":"","overall_status":"RECRUITING","enrollment_count":1155,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT07233928","title":"Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT05216432","title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":930,"lead_sponsor_name":"Relay Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07528768","title":"Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"AntiCancer Research Jamaica","has_results":false},{"nct_id":"NCT07340541","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04526587","title":"Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06982521","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Relay Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06016738","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07347600","title":"A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07030569","title":"RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05563220","title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":435,"lead_sponsor_name":"Stemline Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05907681","title":"Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06533826","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":357,"lead_sponsor_name":"Ana C Garrido-Castro, MD","has_results":false},{"nct_id":"NCT06135714","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Tokyo Medical and Dental University","has_results":false},{"nct_id":"NCT07222215","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":297,"lead_sponsor_name":"Kristina A. Fanucci","has_results":false},{"nct_id":"NCT01048918","title":"Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06500455","title":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":269,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT07366840","title":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":268,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07318805","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03910712","title":"Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07386938","title":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":246,"lead_sponsor_name":"R-Pharm","has_results":false},{"nct_id":"NCT05215769","title":"A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":243,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT05796973","title":"Measuring Oncological Value of Exercise and Statin","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT05346861","title":"Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06683404","title":"GISEL:Registry of Breast Cancer Patients Treated With ECT","phase":"","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT04571437","title":"Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":204,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04609540","title":"Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT06507930","title":"The COMPASSION Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT01881230","title":"Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT06942234","title":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02202746","title":"A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":178,"lead_sponsor_name":"Clovis Oncology, Inc.","has_results":true},{"nct_id":"NCT06201234","title":"Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"GBG Forschungs GmbH","has_results":false},{"nct_id":"NCT06062498","title":"Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT04297384","title":"Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05142800","title":"Screening For BCRL In Targeted Therapy For Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":166,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05303129","title":"Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.","phase":"NA","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT04906369","title":"Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring","phase":"","overall_status":"SUSPENDED","enrollment_count":150,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06369285","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Puma Biotechnology, Inc.","has_results":false},{"nct_id":"NCT03072992","title":"\"Curcumin\" in Combination With Chemotherapy in Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"National Center of Oncology, Armenia","has_results":false},{"nct_id":"NCT06144346","title":"Metastases Directed Therapy for Oligometastatic Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute, Egypt","has_results":false},{"nct_id":"NCT01625286","title":"Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT00313170","title":"A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04316117","title":"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":138,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}